Position in SYRE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$355,120
-$262,721 QoQ
Shares Held
4,000
-89.6% QoQ
Ownership
0.005%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#191
of 265 holders
Holding Since
Mar 2025
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in SYRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026WEXFORD CAPITAL LP holds $6,414,779 across 8 Biotechnology names. SYRE ranks #8 (5.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TRVI |
Trevi Therapeutics, Inc.
|
90,752 | $1,692,524 | |
| 2 | TSHA |
Taysha Gene Therapies, Inc.
|
160,654 | $1,094,053 | |
| 3 | NUVB |
Nuvation Bio Inc.
|
135,889 | $771,849 | |
| 4 | GPCR |
Structure Therapeutics Inc.
|
13,709 | $735,762 | |
| 5 | PRAX |
Praxis Precision Medicines, Inc.
|
2,000 | $669,580 | |
| 6 | PTHS |
Pelthos Therapeutics Inc.
|
22,364 | $632,006 | |
| 7 | ARGX |
Argenx SE
|
500 | $463,885 | |
| 8 | SYRE |
Spyre Therapeutics, Inc.
This page
|
4,000 | $355,120 |
All Filings in SYRE
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $355,120 | 4,000 | Shares | Sole | 2026-08-14 | |
| 2025-03-31 | $617,841 | 38,292 | Shares | Sole | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||